Post-Marketing Commitment(PMC)
A study or clinical trial that a sponsor has agreed to conduct as a commitment to FDA but is not required by statute or regulation.
Usage Examples
- The approval letter included one PMR (pediatric safety study) and three PMCs (additional DDI characterization, renal impairment, and long-term immunogenicity).
- Annual PMC progress reports documented study design finalization and target completion date.
What is PMC?
Post-Marketing Commitments (PMCs) are studies or data collection activities that an NDA or BLA applicant voluntarily agrees to conduct after approval. They are distinct from Post-Marketing Requirements (PMRs), which FDA mandates under FDAAA authority for specific safety purposes. PMCs address FDA questions or knowledge gaps that don't rise to statutory requirement level — additional pharmacokinetic studies, drug-drug interaction data, long-term safety follow-up, or expanded population characterization.
PMCs are typically negotiated during NDA/BLA review and documented in the approval letter. The sponsor reports progress in periodic annual reports and submits final study reports when completed. Missed PMC timelines don't trigger regulatory enforcement the way PMR failures do — but chronic PMC non-completion affects sponsor credibility and can complicate future approval discussions.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDCA SECTION 505O, FDAAA.
When This Matters
- The approval letter included one PMR (pediatric safety study) and three PMCs (additional DDI characterization, renal impairment, and long-term immunogenicity).
- Annual PMC progress reports documented study design finalization and target completion date.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
PMR: FDA mandates under statutory authority, typically for specific safety concerns or pediatric requirements. PMC: sponsor voluntarily agrees to conduct. PMR non-compliance can trigger enforcement; PMC non-compliance affects credibility but has no direct regulatory consequence.
In limited circumstances, yes. If new safety information emerges making the study critical for public health, FDA can invoke FDAAA authority to make it a PMR. This is unusual — typically PMCs stay PMCs throughout their lifecycle.
Yes. PMCs and PMRs are published in FDA's Post-marketing Requirements and Commitments Database and referenced in sponsor annual reports. Progress status (pending, ongoing, completed, delayed) is public information affecting sponsor transparency expectations.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Track every sequence operation, amendment, and supplement across the product lifecycle.
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
NDA, BLA, IND, ANDA, and supplement execution in one workspace.
Sources & References
